CatalYm, eGenesis, and Hansa Biopharma made CFO changes as companies navigate IPO recovery, clinical progression, and capital raising. CatalYm appointed Peter Garcia as CFO, bringing experience that includes raising capital across IPOs and follow-ons; eGenesis selected Glenn S. Vraniak to support clinical studies for engineered organ transplantation; and Hansa Biopharma named Adam Cutler as CFO effective June 22. While these moves vary by company stage, they share a focus on finance leaders with transaction and funding track records. Garcia’s background includes supporting oncology-focused capital markets activity, while Vraniak previously led financing and played roles in major strategic transactions. For the sector, CFO staffing increasingly reflects a shift toward execution readiness for both clinical and market milestones—particularly where companies must balance burn rate with fundraising cadence and potential commercialization timing. The appointments also reinforce that investors are watching governance capacity as a predictor of near-term deal-making and capital strategy.